From Financial Modeling Prep: 2025-03-10 10:05:00

Thomas Shrader from BTIG set a price target of $48 for Arcturus Therapeutics (NASDAQ:ARCT), indicating a significant potential upside from its current trading price of $14.55. However, the company reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate by 226.47%. Revenue for the quarter ending December 2024 was $22.77 million, falling short of expectations by 60.60%. Despite these challenges, ARCT has shown some financial resilience in the past year.



Read more at Financial Modeling Prep:: Arcturus Therapeutics (NASDAQ:ARCT) Financial Over…